The genetic basis of polycystic ovary syndrome

European Journal of Endocrinology

Volumn 147, Issue 6, 2002, Pages 717-725

  Xita, N ^a   Georgiou, I ^a   Tsatsoulis, A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROXYPREGNENOLONE; ANDROGEN RECEPTOR; AROMATASE; CHOLESTEROL; CYTOCHROME P450 17; FOLLISTATIN; INSULIN; INSULIN RECEPTOR; LUTEINIZING HORMONE; PRASTERONE; PREGNENOLONE; PROGESTERONE; STEROID 17,20 LYASE; STEROID 17ALPHA MONOOXYGENASE; STEROID HORMONE; TESTOSTERONE;

BETA CHAIN; CARDIOVASCULAR DISEASE; CHOLESTEROL SIDE CHAIN CLEAVAGE; CLINICAL FEATURE; DYSLIPIDEMIA; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; FEMALE INFERTILITY; GENE CONTROL; GENETIC ASSOCIATION; GENETIC CODE; GENETIC SUSCEPTIBILITY; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RELEASE; MENSTRUAL IRREGULARITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW; RISK ASSESSMENT; STEROIDOGENESIS; VARIABLE NUMBER OF TANDEM REPEAT;

CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; FEMALE; FOLLISTATIN; HUMANS; INSULIN; LUTEINIZING HORMONE, BETA SUBUNIT; POLYCYSTIC OVARY SYNDROME; RECEPTOR, INSULIN; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE;

EID: 0036920310     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1470717     Document Type: Review

References (84)

1. Franks S. Polycystic ovary syndrome. New England Journal of Medicine 1995 333 853-861.
2. Balen A. Pathogenesis of polycystic ovary syndrome - the enigma unravels? Lancet 1999 354 966-967.
3. Zawadzki JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Polycystic Ovary Syndrome, pp 377-384. Eds A Dunaif, JR Givens, F Haseltine & GR Merriam. Boston, MA: Blackwell, 1992.
4. Franks S. Morphology of the polycystic ovary in polycystic ovary syndrome. In Polycystic Ovary Syndrome, pp 19-28. Eds A Dunai, JR Givens, F Haseltine & GR Merriam. Boston, MA: Blackwell, 1992.
5. Farquhar CM, Birdsall M, Manning P, Mitchell JM & France JT. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Australian and New Zealand Journal of Obstetrics and Gynaecology 1994 34 67-72.
6. Solomon CG. The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risk. Endocrinology and Metabolism Clinics of North America 1999 28 247-265.
7. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR & Azziz R. Prevalence of the polycystic ovary syndrome in unselected Black and White women of the Southeastern United States: a prospective study Journal of Clinical Endocrinology and Metabolism 1998 83 3078-3082.
8. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli C, Spina GG et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. Journal of Clinical Endocrinology and Metabolism 1999 84 4006-4011.
9. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S & Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. Journal of Clinical Endocrinology and Metabolism 2000 85 2434-2438.
10. Carmina E, Koyama T, Chang L, Stanczyk FZ & Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? American Journal of Obstetrics and Gynecology 1992 167 1807-1812.
11. Dunaif A, Sorbara L, Delson R & Green G. Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women. Diabetes 1993 42 1462-1468.
12. Williamson K, Gunn A, Johnson N & Milsom SR. The impact of ethnicity on the presentation of polycystic ovarian syndrome. Australian and New Zealand Journal of Obstetrics and Gynaecology 2001 41 201-206.
13. Lobo RA & Carmina E. The importance of diagnosing the polycystic ovary syndrome. Annals of Internal Medicine 2000 132 989-993.
14. Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R et al. The genetic basis of polycystic ovary syndrome. Human Reproduction 1997 12 2641-2648.
15. Ferriman D & Purdie A. The inheritance of PCO and possible relationship to premature balding. Clinical Endocrinology 1979 11 291-300.
16. Carey AH, Chan KL, Short F, White D, Williamson R & Franks S. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clinical Endocrinology 1993 38 653-658.
17. Hague WM, Adams J, Reeders ST, Peto TE & Jacobs HS. Familial polycystic ovaries: a genetic disease. Clinical Endocrinology 1988 29 593-605.
18. Givens JR. Familial polycystic ovarian disease. Endocrinology and Metabolism Clinics of North America 1988 17 771-783.
19. Dunaif A, Segal KR, Futterfeit W & Dobrjansky A. Profound peripheral insulin resistance, independent of obesity in polycystic ovary syndrome. Diabetes 1989 38 1165-1174.
20. Goldfine ID. The insulin receptor: molecular biology and transmembrane signaling. Endocrine Reviews 1987 8 235-255.
21. Talbot JA, Bicknell EJ, Ranjhowa M, Krook A, O'Rahilly S & Clayton RN. Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism 1996 81 1979-1983.
22. Sorbara LR, Tang Z, Cama A, Xia J, Schenker E, Kohanski RA et al. Absence of insulin receptor gene mutations in three women with polycystic ovary syndrome. Metabolism 1994 43 1568-1574.
23. Dunaif A, Xia J & Book C. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome. Journal of Clinical Investigation 1995 96 801-810.
24. Holte J, Bergh T & Berne C. Restored insulin sensitivity but persistent increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1995 80 2586-2593.
25. Junien C & Van Heyningen V. Report of the committee on the genetic constitution of chromosome 11. Cytogenetics and Cell Genetics 1990 55 153-169.
26. Bell GI, Selby MJ & Rutter WJ. The highly polymorphic region near the human insulin gene is composed of simple tandemly repeating sequences. Nature 1982 295 31-35.
27. Paquette J, Giannoukakis N, Polychronakos C, Vafiadis P & Deal C. The INS.5′ variable number of tandem repeats is associated with IGF-II expression in humans. Journal of Biological Chemistry 1998 273 14158-14164.
28. Kennedy G, German MS & Rutter WJ. The minisatellite in the diabetes susceptibility locus IDDM2 regulates insulin transcription. Nature Genetics 1995 9 293-298.
29. Weaver JU, Kopelman PG & Hitman GA. Central obesity and hyperinsulinaemia in women are associated with polymorphism in the 5′ flanking region of the human insulin gene. European Journal of Clinical Investigation 1992 22 265-270.
30. Jowett NI, Williams LG, Hitman GA & Galton DJ. Diabetic hypertriglyceridaemia and related 5′ flanking polymorphisms of insulin gene. British Medical Journal 1984 288 96-99.
31. Ong KL, Phillips DI, Fall C, Pouton J, Bennett ST, Golding J et al. The insulin gene VNTR, type 2 diabetes and birth weight. Nature Genetics 1999 21 262-263.
32. Bennett ST & Todd JA. Human type 1 diabetes and the insulin gene: principles of mapping polygenes. Annual Review of Genetics 1996 30 343-370.
33. Ong KK, Phillips DI, Fall C, Poulton J, Bennett ST, Golding J et al. The insulin gene VNTR, type 2 diabetes and birth weight. Nature Genetics 1999 21 262-263.
34. Waterworth DM, Bennett ST, Gharani N, McCarthy MI, Hague S, Batty S et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997 349 986-990.
35. Robinson S, Kiddy D & Gelding SV. The relationship of insulin sensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clinical Endocrinology 1993 39 351-355.
36. Bennett ST, Todd JA, Waterworth DM, Franks S & McGarthy MI. Association of insulin gene VNTR polymorphism with polycystic ovary syndrome. Lancet 1997 349 1771-1772.
37. Eaves IA, Bennett ST, Forster P, Ferber KM, Ehrmann D, Wilson AJ et al. Transmission ratio distortion at the INS-IGF2 VNTR. Nature Genetics 1999 22 324-325.
38. Michelmore K, Ong K, Mason S, Bennett S, Perry L, Vessey M et al. Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clinical Endocrinology 2001 55 439-446.
39. Rosenfield RL, Barnes RB, Cara JF & Lucky AW. Dysregulation of cytochrome P450c17α as the cause of polycystic ovarian syndrome. Fertility and Sterility 1990 53 785-791.
40. Rosenfield RL, Barnes RB & Ehrmann DA. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing-hormone agonist challenge in functional ovarian hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 1994 79 1686-1692.
41. Miller WL. Molecular biology of steroid hormone synthesis. Endocrine Reviews 1988 9 295-318.
42. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Human Molecular Genetics 1994 3 1873-1876.
43. Gharani N, Waterworth DM, Williamson R & Franks S. 5′ Polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. Journal of Clinical Endocrinology Metabolism 1996 81 4174.
44. Znang LH, Rodriguez H, Ohno S & Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and polycystic ovary syndrome. PNAS 1995 92 10619-10623.
45. Gilling-Smith C, Willis DS, Beard RW & Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. Journal of Clinical Endocrinology and Metabolism 1994 79 1158-1165.
46. Gharani N, Waterworth DM, Batty S, White D, Gilling-Smith C, Conway GS et al. Association of the steroid synthesis gene CYP11α with polycystic ovary syndrome and hyperandrogenism. Human Molecular Genetics 1997 6 397-402.
47. n at - 528 base pairs of gene CYP11α influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertility and Sterility 2000 73 735-741.
48. Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. PNAS 1999 96 8573-8578.
49. n polymorphism in the promoter of the CYP11α gene in the pathogenesis of hirsutism. Fertility and Sterility 2001 75 797-802.
50. Nebert DW, Nelson DR, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ et al. The P450 gene superfamily: recommended nomenclature. DNA 1989 8 1-13.
51. Harada N, Ogawa H, Shozu M & Yamada K. Genetic studies to characterize the origin of the mutation in placental aromatase deficiency. American Journal of Human Genetics 1992 52 666-672.
52. Ito Y, Fisher CR, Conte FA, Grumbach MM & Simpson ER. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. PNAS 1993 90 11673-11677.
53. Takayama K, Tao T & Hironobu S. Immunohistochemical study of steroidogenesis and proliferation in polycystic ovarian syndrome. Human Reproduction 1996 11 1387-1392.
54. Mason HD, Willis DS, Beard RW, Winston RML, Margara R & Franks S. Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle and concentrations of gonadotropins and sex steroids in follicular fluid. Journal of Clinical Endocrinology and Metabolism 1994 79 1355-1360.
55. Balen Ah, Tan SL & Jacobs HS. Hypersecretion of luteinizing hormone: a significant cause of infertility and miscarriage. British Journal of Obstetrics and Gynaecology 1995 100 1082-1089.
56. Furui K, Suganuma N, Tsukahara S, Asada Y, Kikkawa F, Tanaka M et al. Identification of two point mutations in the gene coding luteinizing hormone (LH) β-subunit, associated with immunologically anomalous LH variants. Journal of Clinical Endocrinology and Metabolism 1994 78 107-113.
57. Okuda K, Yamada T, Imoto H, Komatsubara H & Sugimoto O. Antigen alteration of an anomalous human luteinizing hormone caused by two gonadotropin-type amino-acid substitutions. Biochemical and Biophysical Research Communications 1994 200 584-590.
58. Nilsson C, Pettersson K, Millar R, Coerver K, Matzuk M & Huhtaniemi I. Worldwide frequency of a common genetic variant of luteinizing hormone: an international collaborative research. Fertility and Sterility 1997 67 998-1004.
59. Haavisto A, Pettersson K, Bergendahl M, Virkamaki A & Huhtaniemi I. Occurrence and biological properties of a common genetic variant of luteinizing hormone. Journal of Clinical Endocrinology and Metabolism 1995 80 1257-1263.
60. Rajkhowa M, Talbot JA, Jones PW, Pettersson K, Haavisto AM, Huhtaniemi I et al. Prevalence of an immunological LH β-subunit variant in a UK population of healthy women and women with polycystic ovary syndrome. Clinical Endocrinology 1995 43 297-303.
61. Tapanainen JS, Koivunen R, Fauser BC, Taylor AE, Clayton RN, Rajkowa M et al. A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone. Journal of Clinical Endocrinology and Metabolism 1999 84 1711-1715.
62. Ramanujam LN, Liao WX, Roy AC, Loganath A, Goh HH & Ng SC. Association of molecular variants of luteinizing hormone with menstrual disorders. Clinical Endocrinology 1999 51 243-246.
63. Liao WX, Roy AC, Chan C, Arulkumaran S & Ratnam SS. A new molecular variant of luteinizing hormone associated with female infertility. Fertility and Sterility 1998 69 102-106.
64. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS & Wilson EM. Cloning of human androgen receptor complementary DNA and localization on the X chromosome. Science 1988 240 327-330.
65. Brown CJ, Goss SJ, Lubahm DB, Joseph DR, Wilson EM, French FS et al. Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. American Journal of Human Genetics 1989 44 264-269.
66. Carson-Jurica MA, Schrader WT & O'Malley BW. Steroid receptor family: structure and function. Endocrine Reviews 1990 11 201-218.
67. Edwards A, Hammond HA, Jin L, Caskey T & Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992 12 241-253.
68. Chamberlain NL, Driver ED & Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Research 1994 22 3181-3186.
69. LaSpada AR, Wilson EM, Lubahn DB, Harding AE & Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991 352 77-79.
70. Giovannucci E, Stamfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. PNAS 1997 94 3320-3323.
71. Dowsing AT, Yong EL, McLachlan RI, de Kretser D & Trounson A. Linkage between male infertility and trinucleotide repeat expansion in the androgen receptor gene. Lancet 1999 354 640-643.
72. Legro RS, Shahbahrami B, Lobo RA & Kovacs BW. Size polymorphisms of the androgen receptor among female Hispanics and correlation with androgenic characteristics. Obstetrics and Gynecology 1994 83 701-706.
73. Sawaya ME & Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism and acne. Journal of Cutaneous Medicine and Surgery 1998 3 9-15.
74. Vottero A, Stratakis CA, Ghizzoni L, Longui CA, Karl M & Chrousos GP. Androgen receptor-mediated hypersensitivity to androgens in women with nonhyperandrogenic hirsutism: skewing of X-chromosome inactivation. Journal of Clinical Endocrinology and Metabolism 1999 84 1091-1095.
75. Misfud A, Ramirez S & Yong EL. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. Journal of Clinical Endocrinology and Metabolism 2000 85 3484-3488.
76. Shimonaka M, Inouye S, Shimasaki S & Ling N. Follistatin binds to both activin and inhibin through the common beta-subunit. Endocrinology 1991 128 3313-3315.
77. Mather JP, Moore A & Li RH. Activins, inhibins and follistatins: further thoughts on a growing family of regulators. Proceedings of the Society for Experimental Biology and Medicine 1997 215 209-222.
78. Shibata H, Kanzaki M, Takeuchi T, Miyazaki J & Kojima I. Two distinct signaling pathways activated by activin A in glucose responsive pancreatic beta-cells lines. Journal of Molecular Endocrinology 1996 16 249-258.
79. Guo Q, Kuma TR, Woodruff T, Hadsell LA, DeMayo FJ & Matzuk MM. Overexpression of mouse follistatin causes reproductive defects in transgenic mice. Molecular Endocrinology 1998 12 96-106.
80. Urbanek M, Wu X, Vickery KR, Kao LC, Christenson LK, Schneyer A et al. Allelic variants of the follistatin gene in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2000 85 4455-4461.
81. Calvo RM, Villuedas G, Sancho J, San Milian JL, & Escobar-Morreale HF. Role of the follistatin gene in women with polycystic ovary syndrome. Fertility and Sterility 2001 75 1020-1023.
82. Takakura K, Takebayashi K, Wang HQ, Kimura F, Kassahara K & Noda Y. Follicle stimulating hormone receptor gene mutations are rare in Japanese women with premature ovarian failure and polycystic ovary syndrome. Fertility and Sterility 2001 75 207-209.
83. Conway GS, Conway E, Walker C, Hoppner W, Gromoll J & Simoni M. Mutation screening and isoform prevalence of the follicle stimulating hormone receptor gene in women with premature ovarian failure, resistant ovary syndrome atid polycystic ovary syndrome. Clinical Endocrinology 1999 51 97-99.
84. Oksanen L, Tiitinen A, Kaprio, J, Koistinen HA, Karonen S & Kontula K. No evidence for mutations of the leptin or leptin receptor genes in women with polycystic ovary syndrome. Molecular Human Reproduction 2000 6 873-876.